SNDX - Syndax Pharmaceuticals Inc Stock Price, Fair Value and News

$19.70+0.91 (+4.84%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SNDX Price Action

Last 7 days

-0.9%

Last 30 days

43.2%

Last 90 days

21.7%

Trailing 12 Months

18.5%

SNDX RSI Chart

SNDX Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-5.5

Price/Sales (Trailing)

15.35

Price/Free Cashflow

-5.51

SNDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SNDX Fundamentals

SNDX Revenue

Revenue (TTM)

111.6M

SNDX Earnings

Earnings (TTM)

-311.6M

Earnings Growth (Yr)

27.83%

Earnings Growth (Qtr)

15.49%

SNDX Profitability

Return on Equity

-269.93%

Return on Assets

-56.47%

Free Cashflow Yield

-18.16%

SNDX Investor Care

Shares Dilution (1Y)

1.57%

Diluted EPS (TTM)

-3.6

SNDX Alerts

Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	50.9M	78.2M	111.6M	0
2024	0	101.0M	62.4M	23.7M
2021	1.5M	1.5M	13.5M	139.7M
2020	1.5M	1.5M	1.5M	1.5M
2019	1.5M	1.5M	1.5M	1.5M
2018	2.2M	2.3M	2.3M	1.5M
2017	1.2M	1.2M	1.2M	2.1M
2016	775.3K	923.5K	1.1M	1.2M
2015	0	0	0	627.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Michael A. Metzger M.B.A.
WEBSITE	syndax.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	107

Syndax Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Syndax Pharmaceuticals Inc? What does SNDX stand for in stocks?

SNDX is the stock ticker symbol of Syndax Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Syndax Pharmaceuticals Inc (SNDX)?

As of Wed Dec 03 2025, market cap of Syndax Pharmaceuticals Inc is 1.71 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNDX stock?

You can check SNDX's fair value in chart for subscribers.

Is Syndax Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SNDX is over valued or under valued. Whether Syndax Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Syndax Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNDX.

What is Syndax Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, SNDX's PE ratio (Price to Earnings) is -5.5 and Price to Sales (PS) ratio is 15.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNDX PE ratio will change depending on the future growth rate expectations of investors.